Cordance Medical appoints Ryan Dittamore as Chief Executive Officer

Mountain View, Calif. – Cordance Medical today announced that Ryan Dittamore has joined the company as chief executive officer. After founding the company and serving three years in the role, Bhaskar Ramamurthy, Ph.D., will serve as the company’s Chief Technology Officer. 

“Under Bhaskar’s leadership, Cordance has made tremendous progress in generating IP and developing the company’s prototype drug delivery device,” said Michael D. Lesh, MD, Executive Chairman of Cordance Medial. “As Bhaskar continues to drive the technology and product development of the Cordance device, we welcome Ryan to the team as we seek to transition into pre-clincial and clinical development of the device.  Cordance will benefit greatly from Ryan’s strong performance in developing, partnering, and commercializing medical products as we take Cordance to the clinic.”

Mr. Dittamore joins Cordance with over 20 years of experience and has developed and commercialized multiple oncology products utilized in medicine today.  Most recently, he was CBO of Decipher Biosciences, acquired by Veracyte ($600M), and previously Chief of Medical Innovation at Epic Sciences, where he led the clinical development, reimbursement, guideline support, and commercial partnering of the AR-V7 test (the first predictive test in prostate cancer).  Ryan has also held roles at Roche Dx (Ventana), Genisphere (Code Biotherapeutics), and Bio-Rad Labs.  Cumulatively, he has partnered with over 60 biopharma companies, is the author of over 30 peer-reviewed publications, and inventor of 12 patents issued and pending.

“Cordance is a wonderful position with strong core IP and product designs that can enable us to transform the treatment for CNS diseases including brain cancers, Alzheimer’s disease, Parkinson’s disease, and epilepsy,” said Mr. Dittamore. “I’m thrilled to join such a strong team where we are poised to make an impact into one of the great healthcare challenges of our generation.”